This article first appeared on GuruFocus.

Revenue: Increased by 19% to $3.9 million compared to $3.3 million in the prior quarter.

Gross Profit: Totaled $3.2 million, up 29.4% from $2.5 million in the prior year period.

Gross Profit Percentage: Improved by 660 basis points to 81.9% from 75.3% in the prior year quarter.

Operating Expenses: Increased by 5.1% to $2.9 million from $2.8 million in the same period last year.

SG&A Expenses: Increased by 2.5%, with an additional spending of over $56,000 for the quarter.

R&D Expenses: Increased by $84,000.

EBITDA: Achieved $373,000, corresponding to $0.14 per share.

Net Loss: Attributable to common shareholders was $772,000, compared to $1.6 million in the prior year period.

Loss Per Share: Reported a loss of $0.29 compared to $0.73 in the prior year period.

Warning! GuruFocus has detected 5 Warning Signs with BTCY.

Is BTCY fairly valued? Test your thesis with our free DCF calculator.

Release Date: November 14, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Biotricity Inc (BTCY) reported a 19% increase in revenue for the second quarter of fiscal 2026, reaching $3.9 million, driven by strong market adoption of their Technology-as-a-Service subscription model.

The company achieved a gross profit of $3.2 million, up 29.4% from the prior year, with a gross profit percentage improvement of 660 basis points to 81.9%.

Biotricity Inc (BTCY) has achieved positive EBITDA for the second consecutive quarter, with $373,000 reported this quarter, indicating progress towards full profitability.

The company is expanding its market presence through strategic partnerships, including contracts with the VA and leading home care groups, and is actively pursuing geographic expansion.

Biotricity Inc (BTCY) is focused on innovation, with ongoing development of next-generation diagnostic technologies, including the Biocore Pro 2 cardiac monitor, which is expected to be filed for FDA approval by the end of Q1 next year.

Despite improvements, Biotricity Inc (BTCY) reported a net loss attributable to common shareholders of $772,000 for the fiscal 3-month period.

Operating expenses increased by 5.1% to $2.9 million compared to the same period last year, with SG&A expenses rising by 2.5%.

The company is still in the process of achieving full profitability, with a focus on scaling the business and investing in commercial expansion.

Biotricity Inc (BTCY) faces the challenge of maintaining margins while scaling operations and expanding its commercial team.

The company is reliant on the successful commercialization of its Biocore, Bioflux, and Biocare products to drive future growth and profitability.

Q: Can you elaborate on the strategic initiatives that have contributed to the revenue growth this quarter? A: Dr. Waqaas Al-Siddiq, CEO, explained that the revenue growth was driven by the strong market adoption of their Technology-as-a-Service subscription model and the popularity of their FDA-cleared cardiac monitoring devices, particularly the next-gen Biocore Pro. Strategic partnerships and operational efficiencies also played a significant role.

Q: What are the key factors contributing to the improvement in gross profit margins? A: John Ayanoglou, CFO, noted that the gross profit margin improved due to the expansion of their recurring technology fee revenue base, efficiencies gained through proprietary AI, and improvements in their monitoring and cloud cost structure.

Q: How is Biotricity planning to achieve profitability in the near future? A: Dr. Waqaas Al-Siddiq, CEO, stated that they are on the cusp of profitability due to economies of scale, increasing revenues, and maintaining margins. They plan to invest profits into commercial expansion to drive growth and market share.

Q: What are the future plans for product development and innovation? A: Dr. Waqaas Al-Siddiq, CEO, mentioned that they are developing a multiparameter cardiac monitor and finalizing Biocore Pro 2, which they expect to file for FDA approval by the end of Q1 next year. They continue to focus on honing their AI clinical model and developing next-generation diagnostic technologies.

Q: Can you provide more details on the company's sales strategy and market expansion efforts? A: John Ayanoglou, CFO, highlighted that their sales strategy includes transforming their sales force to focus on longer sales cycles in larger accounts, including independent hospitals and GPO networks. They are contracted under three of the largest GPO networks, providing access to over 90% of hospitals in the US. They are also exploring opportunities to expand their geographic footprint and into other verticals that align with their core business.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.